BR112012017310A2 - derivados de triazol substituídos como moduladores de gama secretase - Google Patents

derivados de triazol substituídos como moduladores de gama secretase

Info

Publication number
BR112012017310A2
BR112012017310A2 BR112012017310A BR112012017310A BR112012017310A2 BR 112012017310 A2 BR112012017310 A2 BR 112012017310A2 BR 112012017310 A BR112012017310 A BR 112012017310A BR 112012017310 A BR112012017310 A BR 112012017310A BR 112012017310 A2 BR112012017310 A2 BR 112012017310A2
Authority
BR
Brazil
Prior art keywords
triazole derivatives
gamma secretase
substituted triazole
secretase modulators
compounds
Prior art date
Application number
BR112012017310A
Other languages
English (en)
Inventor
Didier Jean-Claude Berthelot
Henricus Jacobus Maria Gijsen
Michel Anna Jozef De Cleyn
Michel Surkyn
Sven Franciscus Anna Van Brandt
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43569255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017310(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of BR112012017310A2 publication Critical patent/BR112012017310A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

patente de invenção: "derivados de triazol substituídos como moduladores de gama secretase". a presente invenção refere-se a derivados de triazol substituídos da fórmula (i) em que het¹, r¹, r²,a¹,a²,a³,a4, l¹ e l² têm os significados definidos nas reivindicações. os compostos de acordo com a presente invenção são últeis como moduladores de gama secretase. a invenção ainda refere-se a processos para a preparação de tais novos compostos, composições farmacêuticas compreendendo os ditos compostos como um ingrediente ativo bem como o uso dos ditos compostos como um medicamento.
BR112012017310A 2010-01-15 2011-01-12 derivados de triazol substituídos como moduladores de gama secretase BR112012017310A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10150892 2010-01-15
EP10171292 2010-07-29
PCT/EP2011/050350 WO2011086099A1 (en) 2010-01-15 2011-01-12 Novel substituted triazole derivatives as gamma secretase modulators

Publications (1)

Publication Number Publication Date
BR112012017310A2 true BR112012017310A2 (pt) 2016-04-19

Family

ID=43569255

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012017442A BR112012017442A2 (pt) 2010-01-15 2011-01-12 derivados de triazol bicíclicos substituídos como moduladores de gamma secretase
BR112012017310A BR112012017310A2 (pt) 2010-01-15 2011-01-12 derivados de triazol substituídos como moduladores de gama secretase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012017442A BR112012017442A2 (pt) 2010-01-15 2011-01-12 derivados de triazol bicíclicos substituídos como moduladores de gamma secretase

Country Status (20)

Country Link
US (2) US9079886B2 (pt)
EP (2) EP2523955B1 (pt)
JP (2) JP2013517246A (pt)
KR (2) KR20120123677A (pt)
CN (2) CN102906083A (pt)
AR (2) AR079905A1 (pt)
AU (2) AU2011206635B2 (pt)
BR (2) BR112012017442A2 (pt)
CA (2) CA2784769A1 (pt)
CL (2) CL2012001956A1 (pt)
EA (2) EA022093B1 (pt)
ES (2) ES2512840T3 (pt)
IL (2) IL220840A (pt)
MX (2) MX2012008259A (pt)
NZ (2) NZ601150A (pt)
PE (2) PE20121512A1 (pt)
SG (2) SG182505A1 (pt)
TW (2) TWI491608B (pt)
WO (2) WO2011086099A1 (pt)
ZA (2) ZA201205240B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593951A (en) 2009-02-06 2013-01-25 Ortho Mcneil Janssen Pharm Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
CN102439005B (zh) 2009-05-07 2015-07-22 杨森制药公司 作为γ-分泌酶调节剂的取代的吲唑和氮杂-吲唑衍生物
WO2010141796A2 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
EP2454239B1 (en) 2009-07-15 2014-08-13 Janssen Pharmaceuticals Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
MX2012008259A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa.
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
EP2609098B1 (en) * 2010-08-27 2016-07-13 Merck Patent GmbH Triazolopyrazine derivatives
UY33586A (es) 2010-09-02 2012-03-30 Takeda Pharmaceutical Compuesto heterocíclico y sus usos
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
IN2014MN00258A (pt) 2011-07-15 2015-09-25 Janssen Pharmaceuticals Inc
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013124026A1 (en) * 2012-02-21 2013-08-29 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
ES2579981T3 (es) * 2012-03-07 2016-08-18 Merck Patent Gmbh Derivados de triazolopirazina
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
CN103508957B (zh) * 2012-06-25 2017-02-08 中国科学院上海药物研究所 羟乙基吡唑类化合物或氨乙基吡唑类化合物及其制备方法和用途
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
EP2687528A1 (en) 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
JOP20180012A1 (ar) * 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
JP6275161B2 (ja) 2012-12-20 2018-02-07 ヤンセン ファーマシューティカ エヌ．ベー． γセクレターゼ調節剤としての新規な三環式３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
JP6283691B2 (ja) 2013-01-17 2018-02-21 ヤンセン ファーマシューティカ エヌ．ベー． γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体
CN105308037B (zh) * 2013-06-04 2017-09-19 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
ES2701810T3 (es) 2013-06-04 2019-02-26 Acturum Real Estate Ab Compuestos de triazol y su uso como moduladores de gamma-secretasa
CN105263923B (zh) 2013-06-04 2017-06-23 阿克图拉姆生命科学股份公司 嘧啶化合物及它们作为γ分泌酶调节剂的用途
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3227437A4 (en) 2014-12-05 2018-08-22 An2H Discovery Limited Parkin ligase activation methods and compositions
KR101594470B1 (ko) 2015-05-28 2016-02-16 주식회사 네비엔 프리캐스트 콘크리트 슬래브 및 이들의 결합구조
KR101710943B1 (ko) 2016-05-13 2017-02-28 강태성 구조물용 피씨 데크 슬래브 및 이의 제조방법
EP3463347A4 (en) * 2016-06-03 2019-12-18 An2H Discovery Limited TRIAZOLBENZAMID DERIVATIVES AND COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO THIS
CN109311878B (zh) * 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
JP6975514B2 (ja) 2016-07-08 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
US10647721B2 (en) 2016-10-04 2020-05-12 Hoffmann-La Roche Inc. Bicyclic heteroaryl derivatives
JP7132218B2 (ja) * 2016-11-08 2022-09-06 エフ．ホフマン－ラ ロシュ アーゲー フェノキシトリアゾール
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CN110194743B (zh) * 2018-02-26 2022-11-11 云南大学 苯基(3-甲氧基-4-(4-甲基-1h-咪唑-1-基)苯基)甲酮类化合物
CN110194746B (zh) * 2018-02-26 2022-11-18 云南大学 用于治疗阿尔茨海默症的化合物，其制备方法和用途
CN110194744B (zh) * 2018-02-26 2022-11-11 云南大学 一种抑制β-淀粉样蛋白生成的化合物及其制备方法和用途
EP4065581B1 (en) 2019-11-29 2024-07-24 F. Hoffmann-La Roche AG Process for the preparation (9s)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepine
AU2021393968A1 (en) 2020-12-11 2023-05-11 F. Hoffmann-La Roche Ag Process for the preparation of (9s)-n-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amine and its solid form

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
JP4108747B2 (ja) 1995-07-13 2008-06-25 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 治療薬としてのピペラジン誘導体
OA11958A (en) 1999-06-10 2006-04-13 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
WO2001078721A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
JP2006515340A (ja) 2003-02-27 2006-05-25 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｃｒ−３受容体拮抗薬
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
JP2007502257A (ja) 2003-08-14 2007-02-08 エフ．ホフマン−ラ　ロシュ　アーゲー γアミノ酪酸作動性モジュレーター
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
MXPA06013534A (es) 2004-05-26 2007-05-10 Eisai R&D Man Co Ltd Compuesto de cinamida.
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
JP5066514B2 (ja) 2005-03-14 2012-11-07 ハイ ポイント ファーマシューティカルズ，エルエルシー ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
KR20080046209A (ko) 2005-09-22 2008-05-26 사노피-아벤티스 Ｃｃｒ3 수용체 리간드로서의 신규한 아미노-알킬-아미드 유도체
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
US8017805B2 (en) 2005-10-11 2011-09-13 Chemtura Corporation Diaromatic amines
AU2006315718B2 (en) 2005-11-10 2012-10-04 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
WO2007102580A1 (ja) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US7951818B2 (en) 2006-12-01 2011-05-31 Galapagos Nv Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
CN101631779A (zh) * 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
AU2008216842A1 (en) 2007-02-12 2008-08-21 Merck Sharp & Dohme Corp. Piperidine derivatives
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
EP2155740B1 (en) 2007-05-11 2011-01-26 F. Hoffmann-La Roche AG Hetarylanilines as modulators for amyloid beta
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
CA2692253A1 (en) * 2007-06-29 2009-01-08 Schering Corporation Gamma secretase modulators
MY150507A (en) * 2007-08-31 2014-01-30 Eisai R&D Man Co Ltd Polycyclic compound
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
MX2010002674A (es) 2007-09-06 2010-03-25 Schering Corp Moduladores de gamma secretasa.
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
CA2713716A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
AU2009259853A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EP2352731A1 (en) 2008-11-06 2011-08-10 Schering Corporation Gamma secretase modulators
JP5378532B2 (ja) 2008-11-10 2013-12-25 エフ．ホフマン−ラ ロシュ アーゲー 複素環γ−セクレターゼモジュレーター
CN102239165A (zh) 2008-12-03 2011-11-09 维尔制药公司 二酰甘油酰基转移酶抑制剂
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
NZ593951A (en) 2009-02-06 2013-01-25 Ortho Mcneil Janssen Pharm Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
CA2751534A1 (en) 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US20110299830A1 (en) 2009-03-16 2011-12-08 Panasonic Corporation Application running device
EP2424866A1 (en) 2009-04-27 2012-03-07 High Point Pharmaceuticals, LLC Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as -secretase inhibitors
CN102439005B (zh) 2009-05-07 2015-07-22 杨森制药公司 作为γ-分泌酶调节剂的取代的吲唑和氮杂-吲唑衍生物
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
EP2454239B1 (en) 2009-07-15 2014-08-13 Janssen Pharmaceuticals Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
MX2012008259A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa.
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
IN2014MN00258A (pt) 2011-07-15 2015-09-25 Janssen Pharmaceuticals Inc

Also Published As

Publication number Publication date
MX2012008259A (es) 2012-08-17
CN102803261A (zh) 2012-11-28
US20120295901A1 (en) 2012-11-22
JP2013517247A (ja) 2013-05-16
JP2013517246A (ja) 2013-05-16
ZA201205240B (en) 2015-02-25
NZ601150A (en) 2014-06-27
TWI491608B (zh) 2015-07-11
US20120295891A1 (en) 2012-11-22
US9145399B2 (en) 2015-09-29
AU2011206635A1 (en) 2012-07-05
TW201136918A (en) 2011-11-01
SG182506A1 (en) 2012-08-30
TW201134824A (en) 2011-10-16
PE20121512A1 (es) 2012-12-06
ES2523977T3 (es) 2014-12-03
ES2512840T3 (es) 2014-10-24
CN102906083A (zh) 2013-01-30
BR112012017442A2 (pt) 2016-04-19
WO2011086098A1 (en) 2011-07-21
MX2012008260A (es) 2012-08-17
KR20120123677A (ko) 2012-11-09
TWI473807B (zh) 2015-02-21
CA2784769A1 (en) 2011-07-21
KR20130028048A (ko) 2013-03-18
ZA201205245B (en) 2014-12-23
JP5824464B2 (ja) 2015-11-25
EA022093B1 (ru) 2015-10-30
EP2523955B1 (en) 2014-07-16
EA021776B1 (ru) 2015-08-31
AU2011206634A1 (en) 2012-07-19
EA201290655A1 (ru) 2012-12-28
CL2012001955A1 (es) 2012-11-30
AU2011206635B2 (en) 2015-01-22
EP2523949A1 (en) 2012-11-21
CA2784765A1 (en) 2011-07-21
PE20121511A1 (es) 2012-12-06
US9079886B2 (en) 2015-07-14
NZ600648A (en) 2014-06-27
AR079905A1 (es) 2012-02-29
IL220840A (en) 2014-03-31
WO2011086099A1 (en) 2011-07-21
IL220838A0 (en) 2012-08-30
EA201290654A1 (ru) 2012-12-28
SG182505A1 (en) 2012-08-30
AR079904A1 (es) 2012-02-29
CL2012001956A1 (es) 2013-01-25
AU2011206634B2 (en) 2014-11-13
EP2523955A1 (en) 2012-11-21
EP2523949B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
BR112012017310A2 (pt) derivados de triazol substituídos como moduladores de gama secretase
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
EA201171008A1 (ru) Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
MY152998A (en) Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112013023984A2 (pt) derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
EA201270166A1 (ru) Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
MY169986A (en) Benzimidazole-proline derivatives
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BR112012032748A2 (pt) "compostos de piridina anelados"
WO2014101295A3 (zh) 一种詹纳斯激酶（jaks）抑制活性的异恶唑衍生物
BR112012018253A2 (pt) Derivados de ácido 3-heteroaroilamino-propiônico oxigênio-substituídos e seu uso como fármacos
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
BR112013011265A2 (pt) derivados de triazol como ligantes para receptores gaba
BR112017012930A2 (pt) derivados de imidazopiridazina como inibidores de pi3kbeta.
EA201291401A1 (ru) НОВЫЕ ПРОТИВОГРИБКОВЫЕ ПРОИЗВОДНЫЕ 5,6-ДИГИДРО-4-[(ДИФТОРЭТИЛ)ФЕНИЛ]-4H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА И 4-(ДИФТОРЭТИЛ)ФЕНИЛ-6H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
BR112015006243A2 (pt) agentes antibacterianos de fenicol
BR112017013031A2 (pt) derivados de imidazopiridazina ligados à heterociclila como inibidores de pi3kbeta
BR112018075999A2 (pt) derivados de piridina, pirazina e pirimidina bicíclicos como inibidores de pi3k beta

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: JANSSEN PHARMACEUTICALS, INC. (US)